Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological ResponsesChristian Pfister, Stéphane Culine, Gwénaëlle Gravis et al.|European Urology|2020Cited by 246
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†J. Alfred Witjes, Donna E. Hansel, Silke Gillessen et al.|European Urology|2019Cited by 191
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines CommitteesAlan Horwich, Donna E. Hansel, Marek Babjuk et al.|Annals of Oncology|2019Cited by 182